HOME >> MEDICINE >> NEWS
Emory School of Medicine receives $16 million NIH grant to lead biodefense consortium

Emory University School of Medicine has received a grant of $16 million to lead one of five national Cooperative Centers for Translational Research on Human Immunology and Biodefense announced today by the National Institute of Allergy and Infectious Diseases (NIAID). Other institutions in the Emory center include the Institute for Systems Biology in Seattle, Washington; the Institute for Research in Biomedicine in Bellinzona, Switzerland, the Mayo Clinic, and the Centers for Disease Control and Prevention (CDC).

The four-and-a-half year grant is part of $85 million in NIAID awards aimed at a better understanding of the human immune response to potential agents of bioterror and rapid development of counter measures such as vaccines and therapies. The translational centers will focus on moving new findings about immune system function out of the laboratory and into clinical trials.

The Emory-led projects will include studying the human immune response to a vaccine in its entirety, from innate responses to peak immune responses, to the development of long-term immune memory; understanding how a successful vaccine works and using that knowledge to design strategies to enhance vaccine efficacy; and understanding at a cellular level how vaccines lose their effectiveness over time so as to improve the responses of the elderly to vaccination.

Scientists in the Emory consortium will use genomics and proteomics to study the molecular signatures of vaccine-induced innate and adaptive immune responses, says Rafi Ahmed, PhD, director of the Emory Vaccine Center, a Georgia Research Alliance Eminent Scholar, and principal investigator of the Emory grant. "These molecular 'signatures' will help us differentiate between 'good' and 'bad' vaccines," Dr. Ahmed explains. "And this knowledge should allow us to manipulate these immune responses to either enhance immunity in the case of vaccines and immune therapy or to decrease immune responses in autoimmune disease
'"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University Health Sciences Center
17-Sep-2003


Page: 1 2

Related medicine news :

1. Emory Study finds HIV is not an independent risk factor for severe heart disease
2. Emory cardiologists present research at AHA scientific sessions in New Orleans, Nov. 7 - 10
3. Emory study finds mental health and heart disease tightly linked
4. Emory conference to educate health professionals about metabolic syndrome
5. Emory researcher examines effects of antiepileptic drugs on pregnant women and their offspring
6. Emory researchers find race and gender gaps in treatment of heart attack
7. Emory, GlaxoSmithKline, NIMH enter public-private partnership to develop new drugs for depression
8. Emory and CDC scientists explore why most breastfed infants of HIV-positive mothers resist infection
9. Emory scientists find marker for long-term immunity
10. Emory scientists find oral tetrahydrobiopterin can reduce high blood pressure
11. Emory scientists link atrial fibrillation with decrease in nitrous oxide

Post Your Comments:
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable assisted living community, ... from 10:30 a.m. to noon on May 8. , ... St. in Chicago, serves low-income older adults, including those ... independence. , “Mothers, grandmothers, godmothers and mothers-to-be are invited ... Director of Marketing Elizabeth Clippard. , The menu will ...
(Date:4/27/2015)... 2015 Medical Device Design Control , ... Ombu Enterprises**, June 16-17, 2015 – Chicago, IL , ... to a facility today, would the design control system ... is "maybe" or "no" … then very likely there ... a solution. , Take this important step. Enroll ...
(Date:4/27/2015)... How to Implement UDI:, Lessons from Early ... – 3:00 p.m. EDT, http://www.fdanews.com/HowToImplementUDI , With ... restraint, there’s plenty of time to get ready for ... deadlines are coming fast for all devicemakers and soon ... even if it seems there’s no rush. It's already ...
(Date:4/27/2015)... NY (PRWEB) April 28, 2015 ... new white paper called “Website Anatomy 101.” ... paper discusses the necessary design elements for a ... emphasis on responsive design, user experience, search results ... the impact of a well-designed website on patient ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Women may ... from concussion, according to a new study published online ... mild traumatic brain injury (MTBI), is a common medical ... some individuals. , In most cases, patients who ... Ten to 15 percent of MTBI patients will continue ...
Breaking Medicine News(10 mins):Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 2Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 3Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3
(Date:4/27/2015)...  Together with its parent partners and the Community ... initiative of Morris County Prevention is Key (MCPIK), the ... community effort to address the heroin/opiate crisis in ... Volunteer Parent Coaches from the Partnership, ... Denise Mariano , National Council on Alcoholism and Drug ...
(Date:4/27/2015)... 2015 PAML announced today that the ... Axela, Inc. to develop multiplex assays focused on ... of the nation,s leading medical reference laboratories, and ... analysis for clinical diagnostics. Axela,s ... assay development serves as the foundation for novel ...
(Date:4/27/2015)... Calif. , April 27, 2015  Eiger BioPharmaceuticals, ... Phase 2 data of lonafarnib in patients with chronic ... the LOWR HDV program, enrolled at Ankara University Medical ... where HDV is endemic. LOWR HDV ... parallel dose comparison study which randomized subjects to receive ...
Breaking Medicine Technology:Partnership for Drug-Free Kids Brings Life-Saving Kits and Training to New Jersey Families 2Partnership for Drug-Free Kids Brings Life-Saving Kits and Training to New Jersey Families 3PAML and Axela Collaborate on Immune Status for Vaccine Preventable Diseases 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3
Cached News: